Shanghai Pharmaceuticals Holding Co., Ltd
http://english.sphchina.com/index/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shanghai Pharmaceuticals Holding Co., Ltd
Source Innovation And China’s Crouching Tiger Reality In 2022
While China’s increasingly inward-looking macro economic policies and other regulatory hurdles are likely to impact smaller players, positive biopharma policy moves in competing hub contenders including Shanghai and the Greater Bay Area also offer attractive opportunities.
Asia Deal Watch: CJ Group Continues Spree With Majority Stake Acquisition In Batavia Biosciences
Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.
Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
Shanghai Kick-Starts New Consortium To Develop First-In-Class Cancer Drugs
A concerted effort to mobilize the pharma industry, research organizations and state-backed healthcare venture capital firms is under way in Shanghai.
Company Information
- Industry
- Distributors
- Medical Devices
- Pharmaceuticals
- Services
-
Pharmaceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- Beijing Kyuan Pharmaceutical Co., Ltd.
- Cardinal Health China
- Techpool Bio-pharma Co., Ltd
- Shanghai Pharmaceutical Group Co., Ltd.